Your essential biotech, medtech, and pharma recap — no noise, just what matters.

Thursday, November 5, 2026

⚡ Executive Takeaway

Here is Wednesday's number: $124. That is what AstraZeneca reportedly offered, per the Journal, for a company the public market priced at $86.44 at Tuesday's close. Rhythm is exactly the kind of asset this market has refused to pay for: real commercial revenue, a pivotal pipeline, and a balance sheet that just borrowed at SOFR plus 4.60% because equity was closed. A strategic buyer looked at the same package a month ago and bid roughly 43% above where public investors cleared it this week. If the middle of the two ended market is really worthless, nobody told the business development committees. The honest caveats: a single reported offer is not a trend, the status of any talks is unknown, and the 28% move landed inside a policy relief rally that lifted everything from Stryker to Centene, so Wednesday's tape grades nothing cleanly. Still, watch what acquirers do, not what the market pays. The buyers working on ten year horizons just told you where they think the floor under de risked assets sits.

The reported offer against the tape, the post election session in settled closes, and Novo's quarter next to Lilly's, all below. 👉 Read Full Analysis

🧬 AstraZeneca Reportedly Came for Rhythm

The Wall Street Journal reported that AstraZeneca made a $10 billion, $124 per share offer for Rhythm Pharmaceuticals last month; the stock closed up 28.0% at $110.68. RYTM | AZN

The report, carried by Investing.com and Yahoo Finance, says AstraZeneca had previously expressed interest and frames the logic as rare metabolic disease; no comment from either company appears in the coverage, and nothing says whether talks are live. The market did its own underwriting anyway: Rhythm closed at $110.68, up 28.0% from Tuesday's $86.44 by our math from settled closes, which still leaves the stock about 12% below the reported number. The timing is the sharp part. On Tuesday this same company fell 7.5% on its own third quarter, a $750 million private credit facility and a royalty buydown, meaning a strategic reportedly valued Rhythm 43% above what public investors would pay with nearly the same facts in hand.

🗳️ Healthcare's First Post Election Session Was a Melt Up

Stryker rose 9.4%, Medtronic 6.1%, Abbott 5.6% and Boston Scientific 5.3%, our math from settled closes, against a 1.7% S&P, in the first session after Democrats swept both chambers. SYK | MDT | XBI

Reuters tied the move to the sweep: analysts see better odds that the budget law's Medicaid provisions get delayed and that the enhanced ACA subsidies, which expired at the start of the year, come back, with Centene up more than 8% and the hospital chains up 6 to 8% in early trading. J.P. Morgan pushed back that major change is unlikely against a veto. On the pharma side, BioSpace's read from this week's earnings calls is that most favored nation pricing is already embedded: Novo's Mike Doustdar pointed to bipartisan support for the industry, Pfizer's Albert Bourla said he expects no changes to the MFN deals this year, and Leerink flagged that the real exposure is investigations now and renegotiation in 2028, when the voluntary tariff deals expire. The rest of our board: Gilead +4.2%, J&J +3.8%, Amgen +3.7%, AbbVie +3.1%, XBI +2.7%, SPY +1.7%.

💊 Novo's Wegovy Pill Outsold Lilly's Foundayo

Oral Wegovy did DKK 5.39 billion, about $813 million, in the third quarter against $184 million for Foundayo, per pharmaphorum, and Novo moved its full year outlook to within 2% of 2025 levels, which the outlet characterizes as an improvement. NVO | LLY

Group sales rose 4% to DKK 79.2 billion while injectable Wegovy fell 2% and Ozempic fell 5%, so the pill is doing the growing, across just the US, UAE, UK and Germany in its first full quarter. CEO Mike Doustdar called out sales growth in both US and international operations; CagriSema's FDA decision is expected before year end with a US launch planned for early 2027, and the oral candidate zenagamtide, formerly amycretin, has entered Phase 3. A sourcing note we owe you: Novo's 6-K hit EDGAR Wednesday morning, but the three megabyte exhibit defeated our fetches, so every figure here is attributed to pharmaphorum rather than taken from the company announcement. The ADR closed up 5.0% on the sector's big day.

🏭 Lonza Bought Five US Plants From Merck KGaA

Lonza agreed to acquire five US manufacturing sites from Merck KGaA, taking its US CDMO network from four to nine plants, with about 1,100 employees transferring and closing expected mid 2027. Lonza | Merck KGaA

The sites are modality bets: bioconjugates in St. Louis, high potency payload linkers in Madison and Verona, viral vectors with aseptic fill finish in Carlsbad, and lipid nanoparticles, liposomes and PEGylated proteins with fill finish in Indianapolis. Lonza's release puts the enterprise value in the low to mid triple digit millions of Swiss francs, paid in cash with its BBB+ rating intact, and expects around CHF 250 million of sales from the sites in 2028, below group margin until the mid 2030s; on the call, per BioSpace, CEO Wolfgang Wienand pointed to the middle of CHF 100 million to 600 million as roughly the right view and called current utilization way below what is achievable. The deal crossed Tuesday morning and our Tuesday sweep missed it, so it prints tonight a day late. The CDMO consolidation we have tracked since the Vacaville purchase now runs through ADC payloads and gene therapy capacity, onshore.

🫀 TCT Sent Three Datasets Toward the Label

Medtronic's SPYRAL AFFIRM post approval study hit its six month blood pressure endpoints and the FDA added the data to the Symplicity Spyral label, per the company's Tuesday release. MDT | EW | ABT

The 594 patient US study, published in Circulation: Cardiovascular Interventions, showed statistically significant office, home and 24 hour ambulatory blood pressure reductions at six months with no increase in medications, in a cohort that was 45% women and 27% Black. The same TCT produced Edwards' PROGRESS result in NEJM: TAVR beat clinical surveillance in moderate aortic stenosis on death and heart failure events at two years, 16.7% versus 23.9%, with the caveat printed alongside that all cause mortality ran numerically higher with TAVR, 8.4% versus 7.3%. Abbott's Amulet 360 closed 96.3% of left atrial appendages completely at one year and remains under FDA review. Details per MedTech Dive's conference wrap. Medtronic closed up 6.1%, a day after the data and the label update and squarely inside the election rally, so we assign that move no single cause.

📉 Grades, Estates and the Ledger

Amgen's first reaction session closed up 3.7%, the first major this season to clear higher after a beat, but the grade is contaminated: everything rallied. AMGN | PFE | KPTI

We said Wednesday would grade the through line, and the election graded the graders instead: Amgen's 3.7% beat the S&P's 1.7% but trailed Stryker's 9.4%, so whether a delivered quarter earned a premium or just a seat on the policy rally is not knowable from one tape, and the through line carries an asterisk into Friday. Pfizer recovered 2.6% of Tuesday's slide. Karyopharm fell another 17.4% to $0.0729, down 89% from Friday by our math; the interim court orders expected this week could not be verified tonight, with both EDGAR's filing browser and the claims agent's docket refusing our fetches, and the day 74 letter on selinexor is due around November 10. In the IPO ledger, Aspen Neuroscience bounced 3.8% to $12.76, still 14.9% under its offer, Bambusa sat at $16.07, and Zai Lab's closing release stayed absent a ninth night. All percentages ours from settled closes.

📋 Quick Hits

👀 What To Watch Today

📖 In Today's Full Analysis

Be sure to read the full article for all the details, including:

👉 Read the full breakdown →